Close Menu

Getting Closer

Jeremy Grushcow at The Cross-Border Biotech Blog points to the KRAS mutation genetic test to identify patients who won't respond to Erbitux or Vectibix as "exactly how personalized medicine and comparative effectiveness can interact to benefit patients, pharma companies and payors." Grushcow says payors benefit by the elimination of unneces

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.